A new liquid biopsy method has demonstrated the ability to detect more than 95% of stage I and II cancers in a blinded validation cohort, according to proof-of-concept data released by Volition, a multinational epigenetics company.
The technology, called Capture-Seq, works by enriching and purifying plasma samples to produce virtually pure circulating tumor DNA (ctDNA) for sequencing analysis — addressing one of the core challenges in liquid biopsy, where the vast majority of circulating DNA in blood plasma originates from healthy cells rather than tumor cells.